CBD

CBD is a non-psychoactive cannabinoid from Cannabis sativa that modulates the endocannabinoid system. FDA approved Epidiolex for epilepsy. Moderate evidence for anxiety (300mg acute dose reduced social anxiety in a 2011 RCT) and epilepsy (Lennox-Gastaut/Dravet syndromes). CYP3A4 and CYP2C19 inhibitor — significant drug interactions. Liver enzyme elevation at high doses. Unregulated CBD market has quality issues (28% of products tested contained less CBD than labeled, 43% were over-labeled). CRITICAL: inhibits CYP3A4 and CYP2C19 — interacts with warfarin, clobazam, valproate. --- *Reviewed by the Dose AI Research Team and Clinical Advisory Board* *Last updated: 2026-04-06*